Cytokinetics - CYTK Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYTK shares.
View CYTK analyst ratings or view top-rated stocks.

10 equities research analysts have issued twelve-month price targets for Cytokinetics' stock. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they predict the company's stock price to reach $61.73 in the next twelve months. This suggests a possible upside of 27.4% from the stock's current price.
View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts.

Cytokinetics' stock was trading at $45.58 at the beginning of the year. Since then, CYTK stock has increased by 6.3% and is now trading at $48.45.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CYTK earnings forecast.

Cytokinetics, Incorporated (NASDAQ:CYTK) announced its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.81. The biopharmaceutical company earned $88.97 million during the quarter, compared to analysts' expectations of $3.73 million. Cytokinetics had a negative net margin of 142.85% and a negative trailing twelve-month return on equity of 118.37%. The firm's quarterly revenue was up 3029.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.86) earnings per share.

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYTK stock can currently be purchased for approximately $48.45.

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $4.56 billion and generates $70.43 million in revenue each year. The biopharmaceutical company earns $-215,310,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

The company employs 253 workers across the globe.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.